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Up to 40% of referrals from primary care to ‘breast cancer family clinics’ prove to be of women whose assessed risk falls below the
guidelines’ threshold for management in secondary or tertiary care, despite recommendations that they should be screened out at
primary care level. A randomised trial, involving 87 such women referred to the Tayside Familial Breast Cancer Service compared two
ways of communicating risk information, letter or personal interview. Both were found to be acceptable to referred women and to
their family doctors, although the former expressed a slight preference for interview. Only four women returned to their family
doctors with continuing concerns about breast cancer. Nevertheless, understanding of information provided by either route was
unsatisfactory, with apparent confusion about both absolute and relative risks of breast cancer. Substantial minorities appear to
believe that they are at no increased risk at all, or even below the population level of risk, while others remain convinced that their
personal risk has been underestimated. Family history record forms, completed by the referred women, preferably with the assistance
of relatives, are crucial to full assessment of familial risk but one quarter of women referred to the Tayside Familial Breast Cancer
Service currently do not complete and return these forms ahead of their clinic appointment. Further collaboration between primary
care and the Breast Cancer Family Service is required to improve provision for concerned women whose risks fall below the
threshold for special surveillance and to maximise effective use of the family history record form.
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Guidelines published in the UK recommend that women
concerned about a family history of breast cancer should be
assessed first in a primary care setting and only those whose risk
exceeds a specified threshold should be referred to specialist
services for counselling, screening and possible intervention
(Harper, 1996; SIGN, 1998; Eccles et al, 2000; Haites et al, 2000;
NICE, 2004). In reality, however, general practitioners (GPs) find
this ‘gatekeeper’ role difficult, both in the UK (Fry et al, 1999;
Bankhead et al, 2001; Rose et al, 2001; Walter et al, 2001; Elwyn
et al, 2002; Campbell et al, 2003) and elsewhere (Escher and
Sappino, 2000). The proportion of referrals to breast cancer family
clinics that fall below the required risk threshold has been reported
as almost 25% in one large UK-wide survey (Wonderling et al,
2001). For Scottish clinics that figure is 30–40% (Wonderling et al,
2001; Holloway et al, 2004; Reis et al, 2006), the difference
probably being explained by greater ease of extension and
verification of reported family histories in Scotland through access
to the National Cancer Registry and to public records of Births,
Marriages and Deaths (Collyer and DeMay, 1997; Brewster et al,
2004). The term ‘low risk’ is commonly used as shorthand, even in
some official guidelines, to define those falling below the threshold,
although such women are generally at greater risk (up to 1.7 times
higher) than women of comparable age with no family history of
breast cancer.
From its inception in 1994, the Tayside familial breast cancer
clinic (TFBCC) has been a multidisciplinary service run and staffed
jointly by the Departments of Genetics, Breast Surgery and
Radiology. Before this study began, all women referred to the
TBFCC were offered an appointment, even if the family history
appeared to place them at ‘low’ risk. When that assessment was
confirmed, no further follow-up would be arranged, although
clinical examination (sometimes supplemented by mammo-
graphy), was offered before discharge. Inappropriate inclusion of
these ‘lower risk’ women in surveillance programmes probably
does not represent cost-effective use of limited resources (Reis
et al, 2006). However, the need to ‘convey to individuals, especially
those at low risk, accurate information in a sensitive and supportive
manner’ must still be met (Harper, 1996). We report the outcome
of a randomised trial of two approaches to this objective, together
with difficulties encountered and possible solutions.
METHODS
Before the start of the study, which ran for 30 months from August
2000, all General Practices in the Tayside catchment area were
issued with a breast cancer genetics ‘information pack’ developed
by the Cancer Research Campaign (Watson et al, 2001) and Received 14 June 2006; accepted 6 September 2006
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smodified, with the agreement of the authors, to refer specifically
to Scotland. They were also informed by letter and through
presentations at GP study days, and other locally arranged
seminars, about the functions of the breast cancer family clinic
and the planned trial. Continuing information was provided
through the website of the Department of Surgical Oncology,
University of Dundee, and through reports in the Newsletter of the
Tayside Primary Care research Network.
With approval from the Tayside Research Ethics Committee, all
women referred to the TBFCC were invited to participate in a trial,
comparing provision of information about their familial risk by
letter or by personal interview. This would apply only if they
were judged to fall below the 1998 SIGN guidelines threshold for
inclusion in a regular surveillance programme (SIGN and NICE
thresholds are very similar). All referred women also received a
standardised Family History Record form with a request to
complete it as far as possible, preferably in consultation with
relatives, and to return it as the first stage in their risk assessment.
That form, together with the GP referral letter, augmented as
appropriate in each case (and with relevant informed consent) by
checking hospital records, Cancer Registry entries and Registrar
General’s Records of Births, Marriages and Deaths, provided the
basis for a consensus decision, taken by the specialist genetics
staff, whether to offer an appointment to the multi-disciplinary
counselling/surveillance clinic. Enrolment in the trial thus required
written informed consent, a completed Family History Record
form and a clear decision that familial risk was below threshold
level.
Women who met these criteria were randomised by a genetics
associate (using computer-generated random numbers) to receive
the information in a personalised letter or to attend the genetics
department for an interview (with a genetics associate or nurse
specialist) which gave an opportunity for questions to be asked
and answered but did not include clinical breast examination
or mammography. This was followed-up by a personal letter
summarising the discussion. All letters included the information
that, despite being below ‘threshold’ level, risk of breast cancer was
still real. Women should therefore remain ‘breast aware’, report
any breast symptoms promptly to their GP, notify TFBCC of any
change in their family history of breast/ovarian cancer and
participate in the National Breast Screening Programme from
age 50. Letters were copied to the referring GP. The two subgroups
were well matched for age and social class, the latter being assessed
by postcode.
Three months after the letter or interview, participants in the
trial were asked to complete and return a ‘Satisfaction Ques-
tionnaire’, based on the instrument used in the Wales ‘TRACE’
study (Brain et al, 2000; Gray et al, 2000). The constituent elements
are listed in Table 1. They included standardised and validated
measures of psychological health as well as specific reactions to the
service received.
Eighteen months after the end of the trial period, all GPs who
had referred patients included in the trial were asked to complete
and return a short questionnaire to evaluate the service provided
and specifically to gather information on whether the women had
returned to their family doctors with continuing or fresh concerns
about breast cancer.
For data analysis Statistical Package for Social Sciences (SPSSt)
software was used.
RESULTS
During the study period, 380 women were referred to the TBFCC.
Three quarters of these referrals came directly from Primary Care,
the remainder being referred from the symptomatic breast clinic.
Two hundred and eighty-one (74%) returned their ‘Family History
Record’ form but 99 (26%) failed to do so, even after a personal
reminder letter. Around half of these brought the form with them
when they attended the clinic. Of those who did return the form,
64 (23%) did not give written consent to enter the trial. Only 18 of
the 64 actively declined. The remainder simply did not return the
consent document or returned it unsigned. Again, many brought
the signed form to the multidisciplinary clinic but, even if ‘low’
risk status was confirmed, they could not then be randomised.
There were therefore 217 women eligible for the study and, after
full assessment as described above, 90 of these (41.5%) were
judged to be below the guideline threshold level of genetic risk.
They were therefore randomised to ‘letter’ (43) or ‘interview’ (47).
Three were subsequently withdrawn; one, assigned to the ‘letter’
group, was found to have a cancer on initial examination at the
symptomatic breast clinic (she had been referred there because of
vague breast symptoms but family history had been mentioned in
the GP letter and onward referral to the cancer family clinic had
already been arranged, although no ‘low risk’ letter was actually
sent). The other two provided, at interview, new information
shifting them to the ‘moderate’ risk category. Among the other 45
‘low risk’ women interviewed, five gave new information requiring
additional checks on family history and three mentioned breast
symptoms that led to investigation by a breast surgeon but all
remained in the ‘low’ risk category and no significant breast
pathology was found. These data are summarised in Figure 1.
Seventy-one of the 87 randomised study patients (81.6%)
completed and returned the 3 month ‘satisfaction’ questionnaire.
Table 1 Components of patient ‘satisfaction’ questionnaire
Element 1 Concerns about breast cancer Six questions, based on the breast cancer worry scale (Lerman et al (1991)). Each has four possible responses (tick
boxes) indicating degree of worry
Element 2 Actions since receiving risk assessment Twelve questions about possible adverse effects on behaviour. Each has four possible responses indicating
degree of adverse effect
Element 3 Experiences since receiving risk assessment Ten questions about possible positive effects on behaviour. Each has four possible responses, indicating
degree of positive effect
Element 4 Understanding of breast cancer risks Eleven questions, five about perception of own risk, two about perception of general population risk, 1 about
motivation for seeking risk assessment, three about remaining concerns and sharing them with family members. Answers were mainly options to tick or
circle but own and population risk perceptions were presented both as a list of possible odds (‘Inevitable ‘, ‘ 1 chance in 2’, ‘1 chance in 3’ through to
‘1 chance in 100’) and also on a linear percentage scale, from 0 (‘definitely will NOT get it’) through to 100% (‘definitely WILL get it’)
Element 5 Experiences of the interview or written communication(s) with the clinic Twelve questions about amount of information given, whether it was
understandable, whether questions were answered, whether risk given differed from expected, whether the process had helped in coping with
perceived risk and whether the timescale for the process had been acceptable. Responses were mainly in the form of tick boxes with four options but
free text space was included for expression of opinions
Element 6 General Health Questionnaire Twenty-eight item format with four subsections (Goldberg and Williams (1988))
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sThe 87 patients had been referred by 82 GPs, of whom 64 (78%)
responded to the follow-up questionnaire (with replies relating to
69 patients – 79%). Analyses of the responses are presented below.
Patient-completed satisfaction questionnaire
Independent samples t-tests were applied to all comparisons.
‘Concerns about breast cancer’ (6 items). Interitem correlations
were good so the six were averaged to generate an index of breast
cancer concerns. No difference was found between ‘letter’ and
‘face-to-face’ groups, t(69)¼ 0.636, P¼0.527.
‘Actions since referral’ (10 items). Correlations among items
varied but all were significant. No differences between ‘letter’ and
‘face-to-face’ groups were significant.
‘Experiences since referral’ (12 items). Correlations between
items were all significant so scores were averaged. The difference
between averaged scores for ‘letter’ vs ‘face-to-face’ groups did not
reach significance, t(69)¼ 1.676, P¼0.098.
‘Personal breast cancer risk estimate’. There was a significant
difference between ‘letter’ group (mean¼2.0) and ‘face-to-face’
group (mean¼2.38), meaning that those receiving their informa-
tion at interview perceived their risk to be slightly higher than
those informed by letter, t(69)¼ 2.246, P¼0.028.
‘Concern about personal breast cancer risk’. No significant
difference was found between ‘letter’ and ‘face-to-face’ groups,
t(69)¼ 0.705, P¼0.483.
‘Population lifetime risk of breast cancer’. Respondents were
invited to estimate population risk in two formats (see Table 1).
For one of these, five responses were missing. There was no
difference between ‘letter’ and ‘face-to face’ groups for either item,
t(64)¼.424, P¼0.673 and t(69)¼0.194, P¼0.846.
‘Your own lifetime risk of breast cancer’. Again, this question
was posed in two formats. Five responses were missing for
one of these. No significant differences between the trial groups
were found for either format: t(64)¼1.036, P¼0.304 and
t(69)¼ 0.249, P¼0.804. Both population and personal risk
estimates were, however, often wildly inaccurate and there were
poor correlations between estimates expressed in the two different
formats by the same respondent.
‘Satisfaction with the process’. For five of the 12 items in this set
of questions, the ‘face-to-face’ group expressed significantly higher
levels of satisfaction than the ‘letter’ group (P range 0.020–0.001)
although the mean scores for the ‘letter’ group were in the ‘quite
satisfied’ to ‘very satisfied’ range.
‘General Health Questionnaire’. Scores for each of the four
subgroups were summed and a t-test carried out on each. None of
the differences between ‘letter’ and ‘face-to-face’ groups were
significant.
In addition to the above quantifiable responses, women were
invited to provide free text answers to open ended questions about
their reactions to the information given. The majority either left
these text boxes blank or indicated that they were content with the
process. However, 7 (4 from the ‘letter’ and three from the
‘interview’ group) made statements indicating that they now
believed they were at very low risk of breast cancer – possibly less
than that of the general population. (‘I was happy to learn that it
doesn’t run in families and I am more relaxed about everything’.
‘Quite happy that I am at considerably low risk’. ‘Happy to know
my risks are not increased by my mother having developed breast
cancer’.) A further seven (four ‘letter’, three ‘interview’) took the
opposite view and clearly did not accept the judgement that they
were at the lower end of the genetic risk spectrum (‘I cannot feel
reassured by the response I received’. ‘I don’t know if I believe what
you told me; you are giving me a result from statistics which can
prove whatever you want to prove. You are not giving me medical
facts’.)
GP questionnaires
All but two of the 64 GPs declared themselves completely satisfied
with the management of their individual patients. One had some
reservations because of the time that elapsed (several months)
between his referral and communication of the low assessed risk.
Another was dissatisfied because he had no record of the outcome
of his referral (although a copy letter had been sent to him).
When asked how they felt about a policy of evaluating risk
before offering any clinic appointment and of declining appoint-
ments by explanatory letter for those judged to be below
‘threshold’ risk level, 46 of 64 respondents (72%) had no
reservations. Seventeen had some reservations and one had
serious reservations; where specific reasons were given, these
related to the anticipated difficulty for some patients in completing
a standard Family History Record form.
No patient had complained to the GP about the way in which
their risk status had been assessed or communicated and only four
had returned to the GP with concerns about breast cancer in the
18–48 months since receiving their clinic report. Two had fresh
complaints of breast discomfort, which were investigated in the
regional breast unit and two had simply wished to discuss the
information from the genetics clinic. No breast cancers were
recorded at that point but one other patient has subsequently
developed invasive breast cancer at age 62 years.
DISCUSSION
Our findings show that in deriving the best possible estimate of
future cancer risk, face-to-face interview adds little to a detailed
family history form (particularly if completed as a collaborative
project by several relatives) verified and extended by access to
hospital, Cancer Registry and Registrar General’s records. Com-
munication of risk information and its implications, however, still
presents difficulties.
Total referrals
Eligible for trial
(three withdrawn) (offered appointments at multi-
disciplinary clinic)
(consented: risk
assessed as below
threshold)
(mod/high risk
or no family history record form
or no signed consent)
380
90
45 42
37 34
290
Ineligible for trial
RANDOMISED
Interview Letter
Returned
questionnarie
Returned
questionnarie
Figure 1 Distribution of referrals to the Tayside Familial Breast Cancer
Service and recruitment to randomised trial.
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sPatients, whether informed by letter or by interview, seemed to
be very uncertain of their actual risk level some 3 months later, at
least when invited to give it a numerical value. The discrepancies
between two alternative ways of presenting that information may
suggest a lack of clarity in the questions or difficulties with
numerical notation. Communication of risk in the setting of a
breast cancer family clinic is well recognised as a problem area,
with no method of communication proven to achieve accurate
understanding (Watson et al, 1998; Cull et al, 1999; Braithwaite
et al, 2004; Lobb et al, 2005). Furthermore, the free text comments
from a number of respondents showed that, despite scrupulous
avoidance of the term ‘low risk’ in oral and written communica-
tions from the clinic, some feel inappropriately reassured, to the
extent of believing their risk may be below that of the general
population. Conversely, others evidently cannot accept that their
risk does not justify special screening (ineligibility for mammo-
graphy being resented). Overall, the mean level of satisfaction with
the process was acceptable, lying between ‘quite satisfied’ and ‘very
satisfied’, although the scores for the ‘interview’ group were
significantly better than for those receiving the information by
letter. There were no significant differences between ‘letter’ and
‘interview’ in subsequent measures of cancer worry, nor of general
psychological health. Despite the recorded preference for face-to-
face communication, only four women had returned to their GP
with concerns about breast cancer and two of these had been in the
‘interview’ group.
The GP questionnaires revealed no preference for either method
of delivering the risk evaluation and, in general, a process whereby
referred patients were assessed without necessarily being seen in
person at a genetics clinic was considered acceptable.
CONCLUSION
Given that there must be a threshold level of risk below which
clinical and mammographic screening cannot be offered, some
disappointment, and hence dissatisfaction with the service is
inevitable. Studies, including one from Scotland (Julian-Reynier
et al, 1996; Lalloo et al, 1998; McLeish, 2003), have shown that
women with a family history of breast cancer place access to
regular mammography as their highest priority and indeed, so
long as that is provided, they are content to forego specialist
genetic assessment and counselling (Brain et al, 2000). The
counterpart of that is that some women, when told their risk falls
below guidelines’ threshold, will resent exclusion from a surveil-
lance programme. Several women used the free text boxes to
express disappointment that they had not received any screening
or ‘professional examination’ or to comment that they were
relieved to know they would receive regular mammography from
age 40 years (through a workplace or private healthcare scheme).
Our findings in this regard are consistent with those of Scott et al.
(2005) who interviewed a selected group of eight women judged to
be at below threshold risk level and noted that several of them
wished to have their risk ‘up-rated’ so that they would become
eligible for screening.
No procedure, short of providing universal access to regular
mammography, is likely to satisfy all women and any method of
risk assessment will prove flawed in individual cases, as we have
found. Nevertheless, our findings suggest that for most women at
the lower end of the familial risk spectrum, communication of this
information does not require a personal interview. A letter can be
an adequate substitute. There is still scope for improvement
without incurring unjustifiable costs. For example, the letter might
include an invitation to contact the Genetics Centre to discuss
continuing concerns. There may be a place for group sessions with
specialists such as dieticians, counsellors and breast care nurses,
where information on risk reducing ‘lifestyle’ modification may be
offered and questions can be answered. Particular attention must
also be given to methods of explaining risk, perhaps making use
of high quality, specifically designed leaflets. Generic literature
available from patient support groups, cancer charities and other
clinics may also be useful but it will be important to harmonise the
information they contain (Ozakinci et al, 2006).
The concern raised by several GPs about women who find it
difficult to complete a Family History Record needs to be
addressed. The fact that noncompletion of this form previously
guaranteed access to the multidisciplinary clinic was perhaps a
disincentive to its proper use and insistence on return of the form
as a precondition for access to the cancer family service will almost
certainly improve compliance. Rather than simply rejecting
referrals in the absence of a completed form, however, it seems
preferable to enlist the support of the primary care team in
establishing why it has not been returned and in assisting those
with genuine difficulties to collect and collate whatever family
information may be available.
ACKNOWLEDGEMENTS
The study reported in this paper was supported by a grant from
the Scottish Executive Health Department (Chief Scientist Office).
We are grateful to Dr Jonathon Gray and colleagues at the Institute
of Medical Genetics, University Hospital of Wales, Cardiff, for
helpful advice and for permission to use a modified form of the
TRACE questionnaire.
REFERENCES
Bankhead C, Emery J, Qureshi N, Campbell H, Austoker J, Watson E (2001)
New developments in genetics – knowledge, attitudes and information
needs of practice nurses. Fam Pract 18: 475–486
Brain K, Gray J, Norman P, France E, Angilin C, Barton G, Parsons E,
Clarke E, Sweetland H, Tisckowitz M, Myring J, Stansfield K, Webester d,
Gower-Thomas K, Daoud R, Gateby C, Monypenny J, Swingland H,
Branston L, Sampson J, Roberst E, Newcombe R, Cohen D, Rogers C,
Mansel R, Harper P (2000) Randomised trial of a specialist genetic
service for familial breast cancer. J Natl Cancer Inst 92: 1345–1351
Braithwaite D, Emery J, Walter F, Prevost AT, Sutton S (2004) Psychological
impact of genetic counselling for familial cancer: a systematic review and
meta-analysis. J Natl Cancer Inst 96: 122–133
Brewster D, Fordyce A, Black RJ, Scottish Cancer Geneticists (2004) Impact
of a cancer registry-based genealogy service to support clinical genetics
services. Fam Cancer 3: 139–141
Campbell H, Holloway S, Cetnarskyj R, Anderson E, Rush R, Fry A,
Gorman D, Steel M, Porteous M (2003) Referrals of patients with a family
history of breast cancer from primary care to cancer genetics services in
S E Scotland. Br J Cancer 89: 1650–1656
Collyer S, DeMay R (1997) Public records and recognition of genetic
disease in Scotland. Clin Genet 31: 125–131
Cull A, Anderson ED, Campbell S, Mackay J, Smyth E, Steel M
(1999) The impact of genetic counselling about breast cancer
risk on women’s risk perceptions and levels of distress. Br J Cancer 79:
501–508
Eccles DM, Evans DGR, Mackay J, UK Cancer Family Study Group
(2000) Guidelines for a genetic risk-based approach to advising
women with a family history of breast cancer. J Med Genet 37:
203–209
Elwyn G, Iredale R, Gray J (2002) Reactions of GPs to a triage-controlled
referral system for cancer genetics. Fam Pract 19: 65–71
Escher M, Sappino AP (2000) Primary care physicians’ knowledge and
attitudes towards genetic testing for breast-ovarian cancer predisposi-
tion. Ann Oncol 11: 1131–1135
Familial breast cancer
D Young et al
977
British Journal of Cancer (2006) 95(8), 974–978 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sFry A, Campbell H, Gudmunsdottir H, Rush R, Porteous M, Goeman D,
Cull A (1999) GP’s views on their role in cancer genetics services and
current practice. Fam Pract 16: 468–474
Goldberg DP, Williams P (1988) A Users’ Guide to the General Health
Questionnaire. Windsor. NFER-NELSON
Gray J, Brain K, Norman P, Anglim C, France L, Barton G, Branston L,
Parsons E, Clarke A, Sampson J, Roberts E, Newcombe R, Cohen D,
Rogers C, Mansel R, Harper P (2000) A model protocol evaluating the
introduction of genetic assessment for women with a family history of
breast cancer. J Med Genet 37: 192–196
Haites NE, The Cancer genetics subgroup of the Scottish Cancer Group
(2000) Guidelines for regional genetics centres on implementation of
genetics services for breast, ovarian and colorectal cancer families in
Scotland. CME J Gynae Oncol 5: 291–307
Harper P, Genetics and Cancer services (1996) Report of Working Group to
the Chief Medical Officer. London: Department of Health
Holloway S, Porteous M, Cetnarskyj R, Anderson E, Rush R,
Gorman D, Steel M, Campbell H (2004) Patient satisfaction with two
different models of cancer genetic services in south-east Scotland. Br J
Cancer 90: 582–589
Julian-Reynier C, Eisinger F, Chabal F, Aurran Y, Nogues C,
Vennin P, Bognon Y-J, Machelard-Roumagnac M, Mangard-Loubourtin
C, Serin D, Versini S, Mercuri M, Sobol H (1996) Cancer genetics clinics:
target populations and consultees’ expectations. Eur J Cancer 32A:
398–403
Lalloo F, Boggis CRM, Evans DG, Shenton A, Threlfall AG, Howell A (1998)
Screening by mammography, women with a family history of breast
cancer. Eur J Cancer 34: 937–940
Lerman C, Trock B, Rimer BK, Jepson C, Brody D, Boyce A (1991)
Psychological side effects of breast cancer screening. Health Psychol 10:
259–267
Lobb EA, Butow PN, Meiser B, Barratt A, Gaff C, Young MA, Kirk J, Gattas
M, Gleeson M, Tucker K (2005) Women’s preferences and consultants’
communication of risk in consultations about familial breast cancer:
impact on patient outcomes. J Med Genet 40: e56
McLeish L (2003) Demands and Needs of Women Attending two Scottish
Family History Breast Cancer Clinics. MSc Thesis, University of
Manchester: Manchester
NICE (National Institute for Clinical Excellence). Clinical Guideline 14
(2004) The Classification and Care of Women at Risk of Familial Breast
Cancer in Primary, Secondary and Tertiary Care. London
Ozakinci G, Humphris G, Steel CM (2006) Provision of breast cancer risk
information to women at the lower end of the familial risk spectrum.
Community Genet (in press)
Reis MM, Young D, McLeish L, Goudie D, Cook A, Sullivan F, Vysny H,
Fordyce A, Black R, Tavakoli M, Steel M (2006) Analysis of referrals to a
multi-disciplinary breast cancer genetics clinic: practical and economic
considerations. Fam Cancer July 1; [Epub ahead of print]
Rose PW, Watson E, Yudkin P, Emery J, Murphy M, Fuller A, Lucassen A
(2001) Referral of patients with a family history of breast/ovarian cancer
– GPs’ knowledge and expectations. Fam Pract 18: 487–490
Scott S, Prior L, Wood F, Gray J (2005) Repositioning the patient: the
implications of being ‘at risk’. Soc Sci Med 60: 1869–1879
SIGN (Scottish Intercollegiate Guidelines Network) (1998) Breast Cancer in
Women. Edinburgh: SIGN Guideline 29
Walter FM, Kinmonth AL, Hyland F, Murrell P, Marteau TM, Todd C
(2001) Experiences and expectations of the new genetics in relation to
familial risk of breast cancer: a comparison of the views of GPs and
practice nurses. Fam Pract 18: 491–494
Watson E, Clements A, Yudkin P, Rose P, Buckach C, Mackay J, Lucassen
A, Austoker J (2001) Evaluation of the impact of two educational
interventions on GP management of familial breast/ovarian cancer cases:
a cluster randomised controlled trial. Br J Gen Pract 51: 817–821
Watson M, Duvivier V, Wade Walsh M, Ashely S, Davidson J,
Papaikonomou M, Murday V, Sacks N, Eeles R (1998) Family history
of breast cancer: what do women understand and recall about their
genetic risk? J Med Genet 35: 731–738
Wonderling D, Hopwood P, Cull A, Douglas F, Watson M, Burn J, McPherson
K (2001) A descriptive study of UK cancer genetics services: an emerging
clinical response to the new genetics. Br J Cancer 85: 166–170
Familial breast cancer
D Young et al
978
British Journal of Cancer (2006) 95(8), 974–978 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s